Quick Answer
Akebia Therapeutics, Inc. reported Earnings Per Share Diluted of $0.02 (loss) per share for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +93.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $1.28 (loss) per share | Q3 2020: $0.42 (loss) per share | Q1 2021: $0.45 (loss) per share | Q2 2021: $0.51 (loss) per share | Q3 2021: $0.34 (loss) per share | Q1 2022: $0.35 (loss) per share | Q2 2022: $0.15 per share | Q3 2022: $0.29 (loss) per share | Q1 2023: $0.15 (loss) per share | Q2 2023: $0.06 (loss) per share | Q3 2023: $0.08 (loss) per share | Q1 2024: $0.09 (loss) per share | Q2 2024: $0.04 (loss) per share | Q3 2024: $0.10 (loss) per share | Q1 2025: $0.03 per share | Q2 2025: $0.00 per share | Q3 2025: $0.00 per share.
- Over the full 7 years of available data (2019 to 2025), Akebia Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 99.2%.
- Historical annual values: Fiscal year 2025: $0.02 (loss) per share | Fiscal year 2024: $0.33 (loss) per share | Fiscal year 2023: $0.28 (loss) per share | Fiscal year 2022: $0.52 (loss) per share | Fiscal year 2021: $1.70 (loss) per share | Fiscal year 2020: $2.77 (loss) per share | Fiscal year 2019: $2.36 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: